Cellebrite (CLBT) CEO Hogan details large share and option holdings in Form 3

Rhea-AI Filing Summary

Cellebrite DI Ltd. Chief Executive Officer Thomas E. Hogan filed an initial ownership report showing significant equity holdings in the company. He directly holds 693,965 Ordinary Shares, including portions represented by restricted share units that were granted in 2025 and 2026 with vesting schedules extending through 2030.

Hogan also holds stock options over 1,000,000 Ordinary Shares and an additional 500,000 Ordinary Shares at an exercise price of $7.39 per share, expiring on August 6, 2033. Of the 1,000,000-share option grant, 625,000 options are already fully vested and exercisable, with the remainder vesting quarterly through August 7, 2027, while the 500,000-share option grant is fully vested and exercisable.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hogan Thomas E.

(Last) (First) (Middle)

94 SHLOMO SHMELZER ROAD

(Street)

PETAH TIKVA 4970602

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [ CLBT ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares, par value NIS 0.00001 ("Ordinary Shares")	693,965(1)(2)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options	(3)	08/06/2033	Ordinary Shares	1,000,000	$7.39	D
Stock options	(4)	08/06/2033	Ordinary Shares	500,000	$7.39	D

Explanation of Responses:

1. Includes 282,905 Ordinary Shares that are represented by restricted share units ("RSUs") that were granted on September 19, 2025 and vest on July 1, 2026. Each RSU represents a contingent right to receive one Ordinary Share of the Issuer upon settlement.

2. Includes 252,748 Ordinary Shares that are represented by RSUs that were granted on February 10, 2026 and vest as follows: 63,196 vest on the one year anniversary of the grant date and 15,796 vest every three months thereafter through February 10, 2030.

3. Of these stock options, 625,000 are fully vested and exercisable and 62,500 vest on each of May 7, 2026 and every three months thereafter through August 7, 2027.

4. These stock options are fully vested and exercisable.

	/s/ Thomas E. Hogan	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What equity stake does Cellebrite (CLBT) CEO Thomas E. Hogan report on this Form 3?

Thomas E. Hogan reports direct ownership of 693,965 Ordinary Shares of Cellebrite. This figure includes shares represented by restricted share units granted in 2025 and 2026, providing him with meaningful direct equity exposure alongside his option holdings.

What stock options does Cellebrite (CLBT) CEO Thomas E. Hogan hold?

Hogan holds stock options over 1,000,000 Ordinary Shares and a further 500,000 Ordinary Shares at an exercise price of $7.39, expiring on August 6, 2033. These options give him substantial potential future ownership if exercised.

How are Thomas E. Hogan’s Cellebrite (CLBT) stock options vested?

Of the 1,000,000-share option grant, 625,000 options are fully vested and exercisable. The remaining 62,500 options vest on May 7, 2026 and then every three months through August 7, 2027. The separate 500,000-share option grant is fully vested and exercisable.

What restricted share units (RSUs) are included in Thomas E. Hogan’s Cellebrite (CLBT) holdings?

His holdings include 282,905 Ordinary Shares from RSUs granted on September 19, 2025 that vest on July 1, 2026, and 252,748 Ordinary Shares from RSUs granted on February 10, 2026, vesting through February 10, 2030 on a specified quarterly schedule.

Does this Cellebrite (CLBT) Form 3 show new insider buying or selling by the CEO?

The Form 3 records Hogan’s existing holdings and derivative positions rather than new market purchases or sales. It lists his Ordinary Shares, RSUs, and stock options, providing a snapshot of his equity alignment with shareholders at this point in time.

Why is Thomas E. Hogan’s Form 3 for Cellebrite (CLBT) important to investors?

The filing shows the CEO has substantial exposure through Ordinary Shares, RSUs, and large option positions. This level of equity participation can signal alignment with long-term shareholder interests, as his potential rewards are closely linked to Cellebrite’s future share performance.